Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Allogene Therapeutics Inc (Allogene Therapeutics) is a clinical-stage biotechnology company. It primarily focuses on the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune diseases. The company’s pipeline product includes Cemacabtagene Ansegedleucel (cema-cel) which treats hematologic malignancies; ALLO-316 targets CD70+ heme malignancies and other solid tumors; ALLO-213 for small-cell lung cancer and neuroendocrine tumors; ALLO-182 targets gastric and pancreatic cancer and ALLO-329 treats rheumatology disorders. The company operates primarily in the biotechnology and healthcare sectors, focusing on the development and manufacturing of cell therapy products. Allogene Therapeutics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
210 East Grand Avenue, San Francisco, California, 94080
Website
allogene.com
Telephone
1 650 4572700
No of Employees
150
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALLO (NASD)
EPS
XYZ
Net Income (2024)
XYZ
25.9%
(2024 vs 2023)
Market Cap*
$690.3M
Net Profit Margin (2023)
XYZ
-239.9%
(2024 vs 2023)
* As of and is in US$
Allogene Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Hematological Malignancies: |
| Cemacabtagene Ansegedleucel (cema-cel): Hematologic Malignancies |
| ALLO-316: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company expanded its partnership with Foresight Diagnostics to develop a minimal residual disease assay as a companion diagnostic for large B-cell lymphoma treatment with cemacabtagene ansegedleucel (cema-cel). |
| 2024 | Regulatory Approval | In October, the company received the US Food and Drug Administration Regenerative Medicine Advanced Therapy designation to ALLO-316 to treat adult patients with CD70-positive advanced or metastatic renal cell carcinoma. |
| 2024 | Corporate Changes/Expansions | In April, the company was awarded a US$15 million grant from the California Institute for Regenerative Medicine to support the clinical development of ALLO-316, an AlloCAR T product targeting CD70 for advanced or metastatic renal cell carcinoma. |
Competitor Comparison
| Key Parameters | Allogene Therapeutics Inc | Arvinas Inc | Fate Therapeutics Inc | Lyell Immunopharma Inc | Advanced Biotechnologies Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Francisco | New Haven | San Diego | South San Francisco | Eldersburg |
| State/Province | California | Connecticut | California | California | Maryland |
| No. of Employees | 150 | 246 | 161 | 161 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Arie Belldegrun, M.D. | Chairman | Executive Board | 2017 | 75 |
| David Chang, M.D., Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2018 | 65 |
| Geoffrey Parker | Chief Financial Officer; Executive Vice President | Senior Management | 2023 | 60 |
| Christine Cassiano | Chief Communications Officer; Chief Corporate Affairs and Brand Strategy Officer; Executive Vice President | Senior Management | - | - |
| Susie Lundeen | Chief People Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer